TerminatedPhase 2NCT03947255
A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma
Studying Anaplastic large cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Seagen Inc.
- Principal Investigator
- Dominic Lai, MDSeagen Inc.
- Intervention
- brentuximab vedotin(drug)
- Enrollment
- 12 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2022
Study locations (19)
- Pacific Cancer Medical Center, Anaheim, California, United States
- SCL Health Good Samaritan Medical Center Cancer Centers of Colorado, Lafayette, Colorado, United States
- Memorial Cancer Institute, Pembroke Pines, Florida, United States
- Northwest Oncology and Hematology/AMITA, Elk Grove Village, Illinois, United States
- Cardinal Bernardin Cancer Center / Loyola University Medical Center, Maywood, Illinois, United States
- Norton Cancer Institute, Louisville, Kentucky, United States
- Tulane University Hospital and Clinic, New Orleans, Louisiana, United States
- University of Maryland, Baltimore, Maryland, United States
- Karmanos Cancer Institute / Wayne State University, Detroit, Michigan, United States
- Saint Louis University, St Louis, Missouri, United States
- Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
- Summit Medical Group, Florham Park, New Jersey, United States
- Medical University of South Carolina/Hollings Cancer Center, Charleston, South Carolina, United States
- Texas Oncology - Fort Worth, Dallas, Texas, United States
- Texas Oncology - Fort Worth 12th Avenue, Fort Worth, Texas, United States
- +4 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03947255 on ClinicalTrials.govOther trials for Anaplastic large cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT06561048Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell LymphomaCorvus Pharmaceuticals, Inc.
- RECRUITINGPHASE1NCT06494371A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell LymphomaRuijin Hospital
- RECRUITINGPHASE1, PHASE2NCT06137144AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.AstraZeneca
- ACTIVE NOT RECRUITINGPHASE1NCT04526834Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin LymphomaTessa Therapeutics
- ACTIVE NOT RECRUITINGPHASE3NCT04881838CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCLChildren's Cancer Group, China
- ACTIVE NOT RECRUITINGPHASE2NCT02978625Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin CancersNational Cancer Institute (NCI)
- RECRUITINGNCT04220970Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) RegistryThe Lymphoma Academic Research Organisation